| Patent application number | Description | Published |
|---|
| 20080215157 | MODULAR FEMORAL PROVISIONAL - A provisional prosthetic system that replicates the characteristics of a corresponding, nonprovisional femoral prosthesis. The provisional prosthetic system may include a frame component and a shell component. The frame component of the provisional prosthetic system may be configured to be attached directly to a resected femur. In one exemplary embodiment, the frame component is impacted onto the resected femur to firmly seat therewith. Once the frame component is secured to the resected femur, a shell component of the provisional prosthetic system may be positioned on and secured to the frame component. In one exemplary embodiment, the frame component is made from a metallic material. This allows for the frame component to maintain the rigidity necessary to facilitate proper trialing. In another exemplary embodiment, the shell component is a plastic. | 09-04-2008 |
| 20100125339 | TRANSIENTLY MOBILE TIBIAL ENGAGEMENT - The present invention relates to a tibial prosthesis having an articulating component and a tray component. The articulating component is configured for attachment to the tray component. Additionally, the articulating component may be attached to the tray component in a first condition in which the articulating component is at least rotatable relative to the tray component. This allows for the tray component to be attached to the tibia in a position that provides for proper rotation of the tray component with respect to the tibia and/or prevents the tray component from overhanging the resected tibia. Then, the articulating component may be rotated and/or translated to a position that provides for proper alignment of the articulating component with a femoral prosthesis. Once in this positioned, a locking mechanism is used to rotationally fix the articulating component to the tray component. | 05-20-2010 |
| 20100191298 | APPARATUS AND METHOD FOR THE EXTRAMEDULLARY LOCATION OF THE MECHANICAL AXIS OF A FEMUR - A surgical instrument and method determine the orientation of the mechanical axis of a femur. The instrument may include a rod with a first end of the rod rotatably secured at a first point on the surface of distal femur that corresponds to center of the knee joint so that the first end is coincident with the mechanical axis. The connection between the first end of the rod and the distal end of the femur defines a first point of rotation. The second end of the rod is slideably received within a sleeve that is rotatably connected to a support positioned distally away from the distal end of the femur. The connection between the sleeve and the support defines a second point of rotation. When the distance between the first and second points of rotation is minimized, a line drawn therebetween is coincident with the mechanical axis of the femur. | 07-29-2010 |
| 20100191342 | TOTAL KNEE IMPLANT - A knee prosthesis is provided for use in knee arthroplasty. In one exemplary embodiment, the present invention provides a tibial prosthesis having a tibial baseplate with a fixed medial bearing component and a mobile lateral bearing component. In one exemplary embodiment, the lateral bearing component is secured to the lateral portion of the tibial baseplate utilizing at least one prosthetic ligament. Additionally, in one exemplary embodiment, a stop is provided to limit anterior or posterior movement of the lateral bearing component relative to the tibial baseplate. For example, the stop may be defined by cooperating shoulders formed on the lateral bearing and the tibial baseplate. | 07-29-2010 |
| 20110093083 | DISTAL FEMORAL KNEE PROSTHESES - A set of distal femoral knee prostheses which are designed to be more narrow in medial/lateral dimensions with increasing anterior/posterior size than existing prostheses to more closely correspond to the physical anatomy of female patients. The prostheses are designed to have a substantially trapezoidal shape or profile when viewed distally which features a more pronounced narrowing of the medial/lateral dimensions beginning at the posterior end of the prostheses and progressing anteriorly to the anterior end of the prostheses. Additionally, the prostheses each include a reduced profile patellar sulcus and reduced profile anterior condyles to more closely conform to the anatomy of a resected femur, and also include sulcus tracking optimized to conform to female anatomy. | 04-21-2011 |
| 20110196815 | METHODS FOR MANUFACTURING, INVENTORYING, AND SUPPLYING MEDICAL COMPONENTS - The present invention relates to methods for the manufacturing, inventorying, and supplying of medical components. In one exemplary embodiment, the method includes fabricating individual subcomponents of a modular medical device system as finished goods. The finished subcomponents may then be sterilized, stocked, and inventoried and, upon request from a consumer, the individual subcomponents may be supplied to the consumer. For example, the consumer may be a hospital, a surgeon, or a sales representative. Once the individual subcomponents are received by the consumer, the individual subcomponents may then be assembled by the consumer to form a final, implantable medical device. | 08-11-2011 |
| 20110288669 | MASS PRODUCTION OF INDIVIDUALIZED MEDICAL DEVICES - A plurality of individual medical devices is created that define a medical device family. Within the family of medical devices, each of the plurality of medical devices has at least one dimension that, within an acceptable tolerance, is substantially equal to the same dimension of another of the plurality of medical devices. Thus, for each medical device in the family, another, corresponding medical device has at least one substantially similar dimension. For example, a first medical device may have a first value for a dimension and a second medical device may have a second value for the same dimension that is equal to one of the sum of the second dimension and the acceptable tolerance or the difference between the second dimension and the acceptable tolerance. Thus, each of the plurality of medical devices varies from another of the plurality of medical devices by the acceptable tolerance. | 11-24-2011 |
| Patent application number | Description | Published |
|---|
| 20090110875 | Low Thermal Expansion High Strength Honeycomb Cement And Method Therefor - A cement mixture suitable for use with ceramic honeycomb bodies, such as for forming an outer layer on the outer periphery of the honeycomb body, or for forming plugs in the honeycomb body. The cement mixture, when fired, preferably exhibits low coefficient of thermal expansion and high strength. The cement mixture can be applied to a green honeycomb body and simultaneously fired with the green body or can be applied to an already fired ceramic honeycomb body and then fired. Includes cement mixture comprising a plurality of inorganic components comprising talc, kaolin, alumina, silica, and aluminum hydroxide, wherein the mixture contains less than or equal to 18.0% silica and greater than or equal to 17.0% aluminum hydroxide, in percent by weight of the inorganic components. | 04-30-2009 |
| 20090142544 | Honeycomb Cement With Ceramic-Forming Crystallizable Glass And Method Therefor - Disclosed are cements for ceramic honeycomb bodies. Such cements can be applied to a fired ceramic honeycomb body then fired, or can be applied to an unfired (green) honeycomb body and co-fired with the green honeycomb body. The cement can also be used to plug one or more cells in a honeycomb body, wherein the cement can be inserted into a green or a fired ceramic honeycomb body, then fired. Also disclosed are methods of manufacturing a ceramic honeycomb article with the cement. | 06-04-2009 |
| 20090311538 | WEAR RESISTANT COATINGS AND TILES AND METHODS OF MAKING SAME - The various embodiments of the present invention are directed to wear resistant coatings, tiles having the wear resistant coatings disposed thereon, and to methods of making the coatings and tiles. A wear resistant coating generally includes a strontium aluminosilicate glass-ceramic composition that is formed from a glaze. The glaze can include a crystallizing component, which itself can include strontium, aluminum, and silicon, but also comprises less than about 2 weight percent each of lithium, boron, barium, sodium, iron, titanium, zirconium, and carbon, based on a total weight of the crystallizing component. | 12-17-2009 |
| 20120043852 | FLOORING SYSTEMS AND METHODS OF MAKING AND USING SAME - The various embodiments of the present invention are directed to floating floor systems and to methods of making and using the floor systems. The floating floor systems generally include a floating flooring unit ( | 02-23-2012 |
| Patent application number | Description | Published |
|---|
| 20090319776 | TECHNIQUES FOR SECURE NETWORK COMMUNICATION - Techniques for secure network communication are provided. Credentials for a user along with a transparently generated secret are sent to a resource that the user desires to establish a secure communication session with. After successful authentication of the user, an initial sequence number for a first transaction of the session is set on a client of the user. Thereafter, with each transaction of the session the client supplies a new and unique sequence number to a server of the resource and uses the secret to encode and validate that transaction. The server of the resource does not permit any transaction that includes an invalid or previously used sequence number. | 12-24-2009 |
| 20110041171 | TECHNIQUES FOR VIRTUAL REPRESENTATIONAL STATE TRANSFER (REST) INTERFACES - Techniques for virtual Representational State Transfer (REST) interfaces are provided. A proxy is interposed between a client and a REST service over a network. The proxy performs independent authentication of the client and provides credentials to the client and for the client to authenticate to the REST service using a REST service authentication mechanism. The proxy inspects requests and responses and translates the requests and responses into formats expected by the client and the REST service. Moreover, the proxy enforces policy and audits the requests and responses occurring between the client and the REST service over the network. | 02-17-2011 |
| 20110214176 | TECHNIQUES FOR SECURE ACCESS MANAGEMENT IN VIRTUAL ENVIRONMENTS - Techniques for secure access management to virtual environments are provided. A user authenticates to a portal for purposes of establishing a virtual machine (VM). The portal interacts with a cloud server and an identity server to authenticate the user, to acquire an Internet Protocol (IP) address and port number for the VM, and to obtain a secure token. The user then interacts with a secure socket layer virtual private network (SSL VPN) server to establish a SSL VPN session with the VM. The SSL VPN server also authenticates the token through the identity server and acquires dynamic policies to enforce during the SSL VPN session between the user and the VM (the VM managed by the cloud server). | 09-01-2011 |
| 20110231840 | TECHNIQUES FOR SHARING VIRTUAL MACHINE (VM) RESOURCES - Techniques for sharing virtual machine (VM) resources are provided. A relative location for a resource within a VM is created; the relative location dynamically resolves to a particular physical location when a principal requests access to the resource at runtime. The principal is located outside an environment associated with the VM. Authentication and access restrictions are dynamically enforced against the requests made by the principal before a connection is permitted between the principal and the resource (the resource located within the environment of the VM). | 09-22-2011 |
| 20110296486 | DYNAMIC SERVICE ACCESS - Apparatus, systems, and methods may operate to authenticate a desktop client to an identity service (IS), to receive a request, from an application, at the IS via the desktop client for a virtual service internet protocol (IP) address associated with a service. The IS may operate to build a routing token that includes an original physical IP address associated with the service when a policy associated with the IS permits access to the service by a user identity associated with the desktop client. After the routing token is validated, the application may be connected to the service via the desktop client. The application may comprise an e-mail application or a remote control application, such as a virtual network computing (VNC) application. Additional apparatus, systems, and methods are disclosed. | 12-01-2011 |
| 20110296504 | MULTIPLE ACCESS AUTHENTICATION - Apparatus, systems, and methods may operate to receive, at a generating identity provider (IDP), original user credentials sufficient to authenticate a user directly from a user machine, or indirectly from an initial identity provider. Additional activities may include generating, by the generating IDP, generated user credentials having the lifetime of a login session associated with the user, the lifetime initiated approximately when the original user credentials or a token associated with the user are/is validated at the generating IDP. Still further activities may include receiving a request associated with the user during the login session to access an application protected by an agent, and transmitting at least part of the generated user credentials from the generating IDP to the application to authenticate the user to the generating IDP while the login session is not terminated or expired. Additional apparatus, systems, and methods are disclosed. | 12-01-2011 |
| 20120017085 | TECHNIQUES FOR IDENTITY-ENABLED INTERFACE DEPLOYMENT - Techniques for providing identity-enabled interfaces for deployment are presented. Specifically, an agent of an enterprise infrastructure authenticates and acquires an agent identity for interacting with a cloud processing environment. Once the agent is deployed in the cloud processing environment, enterprise policy can be enforced within the cloud processing environment on actions occurring within the cloud. The agent acts as an Application Programming Interface between the enterprise and the cloud processing environment. The reverse is also achievable, where a cloud deploys an agent to the enterprise to deploy a cloud interface within the enterprise for policy enforcement. | 01-19-2012 |
| 20120084844 | FEDERATION CREDENTIAL RESET - Techniques for federated credential reset are presented. A principal requests a credential reset with a first service. The first service provides a link to a third party service previously selected by the principal. The principal separately authenticates to the third party service and cause the third party service to send a federated token to the first service. When the federated token is received by the first service, the first service permits the principal to reset an original credential to a new credential for purposes of accessing the first service. | 04-05-2012 |
| Patent application number | Description | Published |
|---|
| 20110071866 | SYSTEMS AND METHODS FOR DETECTING SUSPECT METER READS IN A PRINT ENVIRONMENT - A system for detecting suspect meter reads in a print environment may include a computing device and a computer-readable storage medium in communication with the computing device. The computer-readable storage medium may include one or more programming instructions for receiving historical meter read values associated with a print-related service, selecting a model set including one or more of the historical meter read values, using a predictive model to determine an anticipated meter read value and a corresponding forecast error value from the model set, determining an updated forecast error value, determining a threshold value, identifying an actual meter read value, determining an average rate associated with the actual meter read value, and flagging the actual meter read value as suspect based on a comparison of the average rate and the threshold value. | 03-24-2011 |
| 20110082722 | METHOD AND SYSTEM TO ASSOCIATE DEVICE MODELS AND ACCOUNTS BY UTILIZATION BANDS - Methods and systems for identifying devices having a specified utilization are disclosed. A selected minimum utilization and maximum utilization defining a utilization band may be received. Device information for each of a plurality of accounts, including a device model and utilization information for each device associated with an account, may also be received. A utilization may be determined for each device based on the utilization information. For each device model in an account, a number of devices in an account having the device model and a utilization in the utilization band may be determined. A plurality of clusters may be identified for device model-account pairs, and at least one device model-account pair may be assigned to a cluster. | 04-07-2011 |
| 20110191144 | SYSTEMS AND METHODS FOR ANALYZING PERFORMANCE OF A PRINT DEVICE IN A MANAGED PRINT SERVICE - A managed print system for analyzing performance of a print device may include a computing device and a computer-readable storage medium in communication with the computing device. The computer-readable storage medium may include one or more programming instructions for receiving a black and white print volume variable associated with a print device, receiving a color print volume variable associated with the print device, determining a black and white cost variable associated with the black and white print volume variable and determining a color cost variable associated with the color print volume variable, determining a standard relationship, determining an empirical relationship, determining, based on the empirical relationship, whether the print device has a poor fit to the standard relationship, and in response to the print device having a poor fit to the standard relationship, determining which of the variables influenced the poor fit. | 08-04-2011 |
| 20110194768 | SYSTEMS AND METHODS TO DETECT MODELS AND ACCOUNTS WITH ANOMALOUS REVENUE FROM COLOR IMPRESSIONS - Methods and systems for identifying device models or accounts exhibiting outlying behavior are disclosed. For a method of identifying a device model exhibiting outlying behavior, a processor may receive a color impression count, a monochrome impression count and either a device model for each of a plurality of devices. A proportion of color revenue may be determined for each device based on the color impression count and the monochrome impression count. The processor may determine, for each device model, a distribution of the proportion of color revenue for the one or more devices having the device model and may automatically identify one or more distributions of the proportion of color revenue exhibiting outlying behavior. Each distribution is associated with a device model. | 08-11-2011 |
| 20110225022 | SYSTEMS AND METHODS FOR DETERMINING PRINT REVENUE BEHAVIOR - Methods and systems for determining print revenue behavior for an account are disclosed. A computing device may determine a print revenue for an account for each of a plurality of time periods. The computing device may select a best fit model from a plurality of models based on the print revenue for the account for the plurality of time periods. The computing device may determine a risk level associated with the account based on a best fit model. The risk level may be based on a difference between the best fit model and the print revenue for the account for each of time period. | 09-15-2011 |
| Patent application number | Description | Published |
|---|
| 20090074726 | MVA EXPRESSING MODIFIED HIV ENVELOPE, GAG, AND POL GENES - The invention provides modified virus Ankara (MVA), a replication-deficient strain of vaccinia virus, expressing human immunodeficiency virus (HIV) env, gag, and pol genes. | 03-19-2009 |
| 20090155250 | MONOCLONAL ANTIBODIES AGAINST ORTHOPOXVIRUSES - The present invention relates to monoclonal antibodies that bind or neutralize Orthopoxviruses. The invention provides such antibodies, fragments of such antibodies retaining B5 or A33 binding ability, fully human antibodies retaining B5 or A33 binding ability, and pharmaceutical compositions including such antibodies. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. Additionally, the invention provides for prophylactic, therapeutic, and diagnostic methods employing the antibodies and nucleic acids of the invention. | 06-18-2009 |
| 20100143402 | INTERGENIC SITES BETWEEN CONSERVED GENES IN THE GENOME OF MODIFIED VACCINIA ANKARA (MVA) VACCINIA VIRUS - The present invention relates to new insertion sites useful for the integration of exogenous sequences into an intergenic region (IGR) of a vaccinia virus genome, where the IGR is located between or is flanked by two adjacent open reading frames (ORFs) of the vaccinia virus genome, and where the ORFs correspond to conserved genes, and to related plasmid vectors useful to insert exogenous DNA into the genome of a vaccinia virus, and further to recombinant vaccinia viruses comprising an exogenous sequence inserted into said new insertion site as a medicine or vaccine. | 06-10-2010 |
| 20110104199 | MVA Expressing Modified HIV Envelope, GAG, and POL Genes - The invention provides modified virus Ankara (MVA), a replication-deficient strain of vaccinia virus, expressing human immunodeficiency virus (HIV) env, gag, and pol genes. | 05-05-2011 |
| 20110243840 | MONOCLONAL ANTIBODIES AGAINST ORTHOPOXVIRUSES - The present invention relates to monoclonal antibodies that bind or neutralize Orthopoxviruses. The invention provides such antibodies, fragments of such antibodies retaining B5 or A33 binding ability, fully human antibodies retaining B5 or A33 binding ability, and pharmaceutical compositions including such antibodies. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. Additionally, the invention provides for prophylactic, therapeutic, and diagnostic methods employing the antibodies and nucleic acids of the invention. | 10-06-2011 |
| Patent application number | Description | Published |
|---|
| 20080255101 | NITRIC OXIDE DONATING DIURETIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE - The invention describes novel compositions and kits comprising at least one nitric oxide enhancing diuretic compound, or pharmaceutically acceptable salts thereof, and, optionally, at least one nitric oxide enhancing compound and/or at least one therapeutic agent. The invention also provides methods for (a) treating conditions resulting from excessive water and/or electrolyte retention; (b) treating cardiovascular diseases; (c) treating renovascular diseases; (d) treating diabetes; (e) treating diseases resulting from oxidative stress; (f) treating endothelial dysfunctions; (g) treating diseases caused by endothelial dysfunctions; (h) treating cirrhosis; (j) treating pre-eclampsia; (k) treating osteoporosis; (l) treating nephropathy; (m) treating peripheral vascular diseases; (n) treating portal hypertension; (o) treating central nervous system disorders; (p) treating metabolic syndrome; (q) treating sexual dysfunctions; and (r) hyperlipidemia. The nitric oxide enhancing diuretic compounds comprise at least one nitric oxide enhancing group linked to the diuretic compound through one or more sites such as carbon, oxygen and/or nitrogen via a bond or moiety that cannot be hydrolyzed. | 10-16-2008 |
| 20090005350 | CYCLOOXYGENASE-2 SELECTIVE INHIBITORS, COMPOSITIONS AND METHODS OF USE - The invention describes novel cyclooxygenase 2 (COX-2) selective inhibitors and novel compositions comprising at least one cyclooxygenase 2 (COX-2) selective inhibitor, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase, and/or at least one therapeutic agent. The invention also provides novel kits comprising at least one COX-2 selective inhibitor, optionally nitrosated and/or nitrosylated, and, optionally, at least one nitric oxide donor, and/or, optionally, at least one therapeutic agent. The novel cyclooxygenase 2 selective inhibitors of the invention can be optionally nitrosated and/or nitrosylated. The invention also provides methods for treating inflammation, pain and fever; for treating and/or improving the gastrointestinal properties of COX-2 selective inhibitors; for facilitating wound healing; for treating and/or preventing renal and/or respiratory toxicity; for treating and/or preventing other disorders resulting from elevated levels of cyclooxygenase-2; and for improving the cardiovascular profile of COX-2 selective inhibitors. | 01-01-2009 |
| 20100093671 | NITROSATED NONSTEROIDAL ANTIINFLAMMATORY COMPOUNDS, COMPOSITIONS AND METHODS OF USE - The invention describes novel nitrosated nonsteroidal antiinflammatory drugs (NSAIDs) and pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitrosated NSAID, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase, and/or at least one therapeutic agent. The invention also provides novel compositions comprising at least one nitrosated NSAID, and at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or at least one therapeutic agent. The invention also provides novel kits comprising at least one nitrosated NSAID, and, optionally, at least one nitric oxide donor and/or at least one therapeutic agent. The invention also provides methods for treating inflammation, pain and fever; for treating gastrointestinal disorders; for facilitating wound healing; for treating and/or preventing gastrointestinal, renal and/or respiratory toxicities resulting from the use of nonsteroidal antiinflammatory compounds; for treating inflammatory disease states and/or disorders; and for treating and/or preventing ophthalmic diseases and/or disorders. | 04-15-2010 |
| 20100093708 | NITROSATED NONSTEROIDAL ANTIINFLAMMATORY COMPOUNDS, COMPOSITIONS AND METHODS OF USE - The invention describes novel nitrosated nonsteroidal antiinflammatory drugs (NSAIDs) and pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitrosated NSAID, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase, and/or at least one therapeutic agent. The invention also provides novel compositions comprising at least one nitrosated NSAID, and at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or at least one therapeutic agent. The invention also provides novel kits comprising at least one nitrosated NSAID, and, optionally, at least one nitric oxide donor and/or at least one therapeutic agent. The invention also provides methods for treating inflammation, pain and fever; for treating gastrointestinal disorders; for facilitating wound healing; for treating and/or preventing gastrointestinal, renal and/or respiratory toxicities resulting from the use of nonsteroidal antiinflammatory compounds; for treating inflammatory disease states and/or disorders; and for treating and/or preventing ophthalmic diseases and/or disorders. | 04-15-2010 |
| 20100137291 | NITROSATED NONSTEROIDAL ANTIINFLAMMATORY COMPOUNDS, COMPOSITIONS AND METHODS OF USE - The invention describes novel nitrosated nonsteroidal antiinflammatory drugs (NSAIDs) and pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitrosated NSAID, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase, and/or at least one therapeutic agent. The invention also provides novel compositions comprising at least one nitrosated NSAID, and at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or at least one therapeutic agent. The invention also provides novel kits comprising at least one nitrosated NSAID, and, optionally, at least one nitric oxide donor and/or at least one therapeutic agent. The invention also provides methods for treating inflammation, pain and fever; for treating gastrointestinal disorders; for facilitating wound healing; for treating and/or preventing gastrointestinal, renal and/or respiratory toxicities resulting from the use of nonsteroidal antiinflammatory compounds; for treating inflammatory disease states and/or disorders; and for treating and/or preventing ophthalmic diseases and/or disorders. | 06-03-2010 |
